PubMed:23994799 JSONTXT

{"project":"Allie","denotations":[{"id":"SS1_23994799_1_0","span":{"begin":129,"end":163},"obj":"expanded"},{"id":"SS2_23994799_1_0","span":{"begin":122,"end":127},"obj":"abbr"}],"relations":[{"id":"AE1_23994799_1_0","pred":"abbreviatedTo","subj":"SS1_23994799_1_0","obj":"SS2_23994799_1_0"}],"text":"Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan.\nFifteen years have passed since discovery of RANKL (receptor activator of NF-κB ligand), resulting in identification of the mechanisms regulating osteoclast differentiation and function. The discovery of RANKL contributed to development of a fully human anti-RANKL monoclonal neutralizing antibody (denosumab). Denosumab has been clinically available for treatment of osteoporosis and cancer-induced bone diseases in the US, Europe and many countries since 2010. In Japan denosumab has been clinically available for treatment of cancer-induced bone diseases since 2012 and it was approved for the treatment of osteoporosis in March 2013. Because RANKL is the absolute factor for osteoclast differentiation, anti-RANKL antibody is very effective and its application is good news for many patients. In this review I described the mechanisms regulating osteoclast differentiation and the strong increase of bone mass in normal mice with anti-mouse RANKL antibody. The single injection of the antibody markedly reduced the number of osteoclasts, inhibited bone resorption, and increased bone mass within several days."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":445,"end":457},"obj":"HP_0000939"},{"id":"T2","span":{"begin":462,"end":468},"obj":"HP_0002664"},{"id":"T3","span":{"begin":606,"end":612},"obj":"HP_0002664"},{"id":"T4","span":{"begin":687,"end":699},"obj":"HP_0000939"}],"text":"Anti-RANKL antibody was approved for the treatment of osteoporosis in Japan.\nFifteen years have passed since discovery of RANKL (receptor activator of NF-κB ligand), resulting in identification of the mechanisms regulating osteoclast differentiation and function. The discovery of RANKL contributed to development of a fully human anti-RANKL monoclonal neutralizing antibody (denosumab). Denosumab has been clinically available for treatment of osteoporosis and cancer-induced bone diseases in the US, Europe and many countries since 2010. In Japan denosumab has been clinically available for treatment of cancer-induced bone diseases since 2012 and it was approved for the treatment of osteoporosis in March 2013. Because RANKL is the absolute factor for osteoclast differentiation, anti-RANKL antibody is very effective and its application is good news for many patients. In this review I described the mechanisms regulating osteoclast differentiation and the strong increase of bone mass in normal mice with anti-mouse RANKL antibody. The single injection of the antibody markedly reduced the number of osteoclasts, inhibited bone resorption, and increased bone mass within several days."}